The Netherlands: Europe’s most attractive and innovative biopharmaceutical industry environment
With an unrivalled concentration of biopharmaceutical ecosystems, world-class universities and a long history of strategic partnerships between science, industry and government, the Netherlands is a perfect location for biopharmaceutical innovation in Europe. Many ground-breaking companies have already established themselves in the Netherlands. The EMA will soon follow in their footsteps and relocate to Amsterdam. This confirms once more that the Netherlands is the perfect home for biopharmaceutical companies all around the globe.
Read all about the advantages of setting up your business in the Netherlands in this special bidbook for the biopharmaceutical industry. It demonstrates all the reasons why the Netherlands is a top location for pharmaceutical operations for those biopharmaceutical companies that are interested in locating their company in the Netherlands.
The Minister of Economic Affairs and Climate policy, Eric Wiebes, underlined this in his foreword: “the pharmaceutical sector plays an important role in our economy and acts as a breeding ground for new talent. Leading pharmaceuticals companies like Janssen, AstraZeneca and Synthon are already conducting their R&D activities here.”
Read the bidbook here on the Health~Holland website.
On 12 March Gerard Schouw, director of the Association Innovative Medicines, handed over the first copy of the bidbook to Nico van Meeteren, executive director of the Top Sector LSH.
The following partners have contributed to the development of the bidbook: AmCham, Association Innovative Medicines, Health~Holland, HollandBIO,
Lygature, Ministry of Economic Affairs and Climate Policy, Netherlands Foreign Investment Agency, VNO-NCW.